Cargando…

Nanoparticle-based modulation of CD4(+) T cell effector and helper functions enhances adoptive immunotherapy

Helper (CD4(+)) T cells perform direct therapeutic functions and augment responses of cells such as cytotoxic (CD8(+)) T cells against a wide variety of diseases and pathogens. Nevertheless, inefficient synthetic technologies for expansion of antigen-specific CD4(+) T cells hinders consistency and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Isser, Ariel, Silver, Aliyah B., Pruitt, Hawley C., Mass, Michal, Elias, Emma H., Aihara, Gohta, Kang, Si-Sim, Bachmann, Niklas, Chen, Ying-Yu, Leonard, Elissa K., Bieler, Joan G., Chaisawangwong, Worarat, Choy, Joseph, Shannon, Sydney R., Gerecht, Sharon, Weber, Jeffrey S., Spangler, Jamie B., Schneck, Jonathan P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568616/
https://www.ncbi.nlm.nih.gov/pubmed/36241639
http://dx.doi.org/10.1038/s41467-022-33597-y
Descripción
Sumario:Helper (CD4(+)) T cells perform direct therapeutic functions and augment responses of cells such as cytotoxic (CD8(+)) T cells against a wide variety of diseases and pathogens. Nevertheless, inefficient synthetic technologies for expansion of antigen-specific CD4(+) T cells hinders consistency and scalability of CD4(+) T cell-based therapies, and complicates mechanistic studies. Here we describe a nanoparticle platform for ex vivo CD4(+) T cell culture that mimics antigen presenting cells (APC) through display of major histocompatibility class II (MHC II) molecules. When combined with soluble co-stimulation signals, MHC II artificial APCs (aAPCs) expand cognate murine CD4(+) T cells, including rare endogenous subsets, to induce potent effector functions in vitro and in vivo. Moreover, MHC II aAPCs provide help signals that enhance antitumor function of aAPC-activated CD8(+) T cells in a mouse tumor model. Lastly, human leukocyte antigen class II-based aAPCs expand rare subsets of functional, antigen-specific human CD4(+) T cells. Overall, MHC II aAPCs provide a promising approach for harnessing targeted CD4(+) T cell responses.